22nd International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

第22届艾滋病毒合并症和药物不良反应国际研讨会

• 批准号: 10082909
• 负责人: TODD T BROWN
• 金额: $ 4.3万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-24 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10082909
• 关键词: Adverse effects; Age; Cardiovascular Diseases; Cause of Death; Chronic; Chronic Disease; Clinical; Clinical Management; Collaborations; Committee Members; Communities; Disease; Educational workshop; Endocrinologist; Etiology; Europe; Feedback; Fostering; Goals; HIV; HIV Infections; Home environment; Inflammation; International; International AIDS; Internet; Liver diseases; Longevity; Mentors; Metabolic Bone Diseases; Metabolism; Molecular; New York; New York City; Obesity; Opportunistic Infections; Oral; Paper; Pathogenesis; Play; Research; Research Personnel; Retroviridae Infections; Risk Factors; Role; Scholarship; Sleep; Societies; Stroke; Training Programs; Translational Research; Travel; Ursidae Family; Work; adverse drug reaction; antiretroviral therapy; career development; clinical practice; co-infection; comorbidity; disability; healthspan; improved; low and middle-income countries; meetings; pediatric cardiologist; peer; posters; programs; research clinical testing; skills; success; symposium

With the success of antiretroviral therapy (ART), comorbid diseases are now the leading causes of death and disability in people living with HIV around the globe, including low and middle income countries (LMIC). Large meetings, such as the Conference for Retroviruses and Opportunistic Infections and the International AIDS Society Conference, are important venues for scientific exchange regarding the latest advances in HIV Comorbidity research, but smaller, more intimate formats that emphasize discussion and networking are critical to the career development of HIV Comorbidity investigators. The International Workshop for Comorbidities and Adverse Drug Reactions in HIV, now in its 22nd year, provides <200 delegates with an opportunity to come together to discuss the latest findings and controversies in HIV Comorbidity research in one-room, two-day format. Plenary speakers are either noted experts from outside of HIV research or HIV researchers with expertise in a specific comorbidity. Abstract presentations including 24 15-minute talks and a poster session provide ample opportunity for researchers to present and get feedback on their latest work. With this R13, we propose to enhance the 22nd Workshop (September 12th/13th in New York) with the following aims: 1) to provide a forum for the latest HIV Comorbidity research in LMIC by offering travel scholarships to LMIC investigators, supporting an internationally-recognized expert in non-communicable diseases in LMIC as a plenary speaker, and liaising with international training programs, 2) to support early-stage investigators with a scholarship program and a research skill building workshop, and guided poster tour, 3) to increase the impact of the Workshop through the webcast of plenary and abstract presentations. By providing a “scientific home” to an increasing number of HIV Comorbidity investigators from around the world, we hope to catalyze future research efforts in HIV Comorbidities and facilitate the translation of research findings into clinical strategies that can improve the lifespan and health span of PLWH.

随着抗逆转录病毒疗法（ART）的成功，合并症现在是主要原因 全球艾滋病毒感染者的死亡和残疾，包括低和中间 收入国家（LMIC）。大型会议，例如逆转录病毒和会议 机会主义感染和国际艾滋病协会会议是重要的场所 有关艾滋病毒合并症研究最新进展的科学交流，但较小，但 强调讨论和网络的更亲密格式对职业至关重要 艾滋病毒合并症研究人员的发展。合并症国际研讨会 现在已有22年的艾滋病毒中的艾滋病毒的不良药物反应为<200代表提供了 有机会聚在一起讨论HIV合并症中最新发现和争议 以一室，两天的格式进行研究。全体演讲者要么是外面的专家 在特定合并症方面具有专业知识的艾滋病毒研究或艾滋病毒研究人员的研究。抽象的 演示文稿，包括24次15分钟的会谈和海报会议，提供了足够的机会 研究人员展示并获得有关其最新工作的反馈。使用此R13，我们建议 增强22届研讨会（纽约9月12日/13日），以下目的：1） 通过提供旅行科学，为LMIC提供了最新的HIV合并症研究论坛 向LMIC调查人员，支持国际公认的非传染性专家 LMIC的疾病作为全体发言人，并与国际培训计划联络，2） 通过科学计划和研究技能建设支持早期研究人员 讲习班和导游的海报之旅，3）增加讲习班的影响 全体和抽象演示的网络广播。通过提供越来越多的“科学家” 来自世界各地的艾滋病毒合并症调查员的数量，我们希望催化未来 艾滋病毒合并症的研究工作，并促进研究结果的转化 可以改善PLWH的寿命和健康跨度的临床策略。